Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2023-05-04 Interim / Quarterly Rep…
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2023
2023-05-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 4, 2023, reporting the issuance of a press release regarding financial results for the quarter ended March 31, 2023. The text explicitly states that the press release is furnished as an exhibit and is not deemed "filed" for certain regulatory purposes. The document itself is short (3260 characters) and primarily serves as a notification of the earnings release rather than containing the financial results or detailed analysis. According to the rules, such a document announcing or furnishing a press release of financial results without substantive financial data should be classified as an Earnings Release (ER). The presence of a press release about quarterly financial results aligns with the definition of an Earnings Release. Therefore, the correct classification is ER with high confidence.
2023-05-04 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a DEFA14A form, which is a Definitive Additional Proxy Statement filed pursuant to Schedule 14A under the Securities Exchange Act of 1934. The text explicitly mentions 'PROXY STATEMENT' and 'Definitive Additional Materials,' indicating it is related to proxy solicitation and shareholder voting information. The document length is short (1145 characters), consistent with proxy solicitation materials rather than a full report. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2023-03-31 English
DEF 14A
Proxy Solicitation & Information Statement
2023-03-31 English
Director's Dealing 2023
Director's Dealing
2023-03-17 English
10-K
Annual Report FY 2022
2023-02-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.